"Risk-reduced business models in the life science industry have become increasingly popular among risk-averse investors and increasingly successful. The "virtual" company model allows companies to manage drug development and marketing with minimal overhead and infrastructure. Some companies rely heavily on in licensing to bring successful drugs from overseas to the United States. Other companies are selectively building drug discovery and development capabilities and outsourcing noncore capabilities only when needed. Back by popular demand, this panel will discuss the strategic decisions biotech companies make to add value, mitigate risk and bring
treatments for life-threatening diseases to patients faster and cheaper than the traditional life sciences company."

Objective1: Present successful business models that mitigate risk.

Objective2: Provide a platform to discuss the pros and cons of traditional vs. nontraditional life sciences companies.

Objective3: Educate on emerging trends for mitigating risk, expediting drug development and adding value for investors.